FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroGen in a research note on Tuesday, March 18th.

FibroGen Stock Performance

NASDAQ FGEN opened at $0.32 on Friday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80. The company has a market capitalization of $31.74 million, a P/E ratio of -0.26 and a beta of 0.82. The company has a fifty day moving average of $0.49 and a 200-day moving average of $0.43.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $3.14 million during the quarter, compared to the consensus estimate of $24.91 million. As a group, analysts forecast that FibroGen will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new stake in FibroGen in the fourth quarter worth about $27,000. Velan Capital Investment Management LP purchased a new stake in FibroGen in the fourth quarter worth about $42,000. XTX Topco Ltd grew its holdings in FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC grew its holdings in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares during the period. Finally, FMR LLC grew its holdings in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the period. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.